ReviewVirology journal2013
Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches.
Review in Virology journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 74 citations in OpenAlex.
- Virus Biomimetic-Delivery Systems for the Production of Vaccines.Biomimetics (Basel, Switzerland) · 2026Review
- Antibody-independent surface plasmon resonance assays for influenza vaccine quality control.Applied microbiology and biotechnology · 2024Review
- Article
- Article
- Bioanalytics for Influenza Virus-Like Particle Characterization and Process Monitoring.Frontiers in bioengineering and biotechnology · 2022Article
- Development and characterization of influenza M2 ectodomain and/or hemagglutinin stalk-based dendritic cell-targeting vaccines.Frontiers in microbiology · 2022Article
- Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures.Vaccines · 2021Article
- Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.Molecular pharmaceutics · 2021Review
- Review
- Development of a New Tandem Ion Exchange and Size Exclusion Chromatography Method To Monitor Vaccine Particle Titer in Cell Culture Media.Analytical chemistry · 2019Article
- Purification of influenza virus-like particles using sulfated cellulose membrane adsorbers.Journal of chemical technology and biotechnology (Oxford, Oxfordshire : 1986) · 2018Article
- Universal type/subtype-specific antibodies for quantitative analyses of neuraminidase in trivalent influenza vaccines.Scientific reports · 2018Article
- Article
- Production of virus-like particles for vaccines.New biotechnology · 2017Review
- Preparation and immunogenicity of influenza virus-like particles using nitrocellulose membrane filtration.Clinical and experimental vaccine research · 2017Article
- Generation of monoclonal pan-hemagglutinin antibodies for the quantification of multiple strains of influenza.PloS one · 2017Article
- Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.Biotechnology journal · 2015Review
- Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems.BMC biotechnology · 2015Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza virus-like particle vaccines are one of the most promising ways to respond to the threat of future influenza pandemics. VLPs are composed of viral antigens but lack nucleic acids making them non-infectious which limit the risk of recombination with wild-type strains. By taking advantage of the advancements in cell culture technologies, the process from strain identification to manufacturing has the potential to be completed rapidly and easily at large scales. After closely reviewing the current research done on influenza VLPs, it is evident that the development of quantification methods has been consistently overlooked. VLP quantification at all stages of the production process has been left to rely on current influenza quantification methods (i.e. Hemagglutination assay (HA), Single Radial Immunodiffusion assay (SRID), NA enzymatic activity assays, Western blot, Electron Microscopy). These are analytical methods developed decades ago for influenza virions and final bulk influenza vaccines. Although these methods are time-consuming and cumbersome they have been sufficient for the characterization of final purified material. Nevertheless, these analytical methods are impractical for in-line process monitoring because VLP concentration in crude samples generally falls out of the range of detection for these methods. This consequently impedes the development of robust influenza-VLP production and purification processes. Thus, development of functional process analytical techniques, applicable at every stage during production, that are compatible with different production platforms is in great need to assess, optimize and exploit the full potential of novel manufacturing platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.